Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Vaak specifieke DNA-afwijkingen bij atypische tumoren Lynch-syndroom
apr 2023 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie